The Warneford Hospital- NIHR Clinical Research Facility
Welcome,         Profile    Billing    Logout  
 4 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Allen, Rebecca H
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT05458037: RCT of Pain Perception With Fast and Slow Tenaculum Application

Recruiting
N/A
150
US
Speed of tenaculum application
Women and Infants Hospital of Rhode Island
Pain, Acute, Pain, Procedural
12/26
12/26
MeRT-TBI-005, NCT02990793: Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Recruiting
N/A
152
US
Active MeRT Treatment, rTMS Active Stimulator, Sham MeRT Treatment, rTMS Sham Stimulator
Wave Neuroscience, Texas A&M University, GilpinPhillips BIOMED, LLC, Peachtree BioResearch Solutions
PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms
07/24
09/24
MiMP, NCT05363371: Minds and Mentors Program- R33

Recruiting
N/A
240
US
Minds and Mentors, Twelve Step Intervention Group
University of Alabama, Tuscaloosa, University of Alabama at Birmingham, Tuscaloosa Veterans Affairs Medical Center, Pathway Healthcare, LLC
Opioid Use Disorder, Substance Use Disorders, Medication Assisted Treatment
08/24
08/24
OLO, NCT05819021: Open Label Optimization Study

Recruiting
N/A
1000
US
SAINT® Neuromodulation System (NMS), TMS
Magnus Medical
Major Depressive Disorder
10/26
04/27
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Mickey, Brian J
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT03684447: Neural and Antidepressant Effects of Propofol

Active, not recruiting
2/3
48
US
Propofol, Diprivan
University of Utah
Treatment Resistant Depression
12/22
07/24
NCT05301036: Personalized Ultrasonic Brain Stimulation for Depression

Active, not recruiting
1/2
20
US
Diadem prototype
University of Utah
Major Depressive Episode
07/24
12/24
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
RuMeChange, NCT03859297: Mechanisms of Rumination Change in Adolescent Depression

Recruiting
N/A
183
US
Rumination-Focused CBT, Relaxation-based Therapy
Ohio State University, University of Exeter, National Institute of Mental Health (NIMH), University of Utah, Nationwide Children's Hospital, Utah Center for Evidence Based Treatment
Major Depressive Disorder, Mood Disorders
04/25
03/26
Okorie, Eugene
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Active, not recruiting
3
1083
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
05/25
05/25
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting
2/3
225
Canada, US
Piromelatine 20 mg, Neu-P11, Placebo
Neurim Pharmaceuticals Ltd., Syneos Health
Alzheimer's Disease
06/25
06/25
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

Completed
2
197
Canada, US
Liafensine, Placebo
Denovo Biopharma LLC
Treatment Resistant Depression
02/24
03/24
Kang, Shimi
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
Youngblood, Katrina
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
Vo, Monica
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
Matte, Raymond
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
Grasswick, Linda
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25

Download Options